{"entity":{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","aka":[],"tldr":"Upgraded CAR-T cells that also secrete immune boosters, resist exhaustion, or only fire when two signals are present.","summary":"Armoured and logic-gated CARs add transgenes or synthetic circuits that change how CAR-T cells behave in the tumour microenvironment: IL-12 or IL-18 secretion, dominant-negative TGF-β receptors, PD-1 knockout, synNotch logic gates (AND/NOT gating for solid tumours, for example Arsenal Bio), and tunable CARs. Each design addresses one of the solid-tumour barriers of exhaustion, immune suppression, or on-target off-tumour toxicity, with logic gating meant to fire only when two antigens are present together. These constructs are designed for hostile solid-tumour environments where first-generation CARs failed. The cost is complexity, and the safety of constitutively secreted cytokines is unresolved, so most programmes are phase 1. The simple version is an upgraded CAR-T that carries its own boosters, armour, or a two-signal safety switch.","status":"phase-1","asOf":"2026-09-04","links":[{"label":"ClinicalTrials.gov NCT03373097: GD2-CART01 (Bambino Gesù phase 1/2)","url":"https://clinicaltrials.gov/study/NCT03373097"}],"tags":["frontier"],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["car-t"],"targets":[],"drugs":[],"companies":["modulari-t","tmunity-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":["car-t"],"notes":[],"principle":"Additional transgenes or synthetic circuits modify CAR-T behaviour in the tumour microenvironment.","strengths":["Designed for hostile solid-tumour environments"],"limitations":["Complexity, safety of constitutive cytokines"]},"route":"/technologies/armored-car/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"glioma-car-t","kind":"technology","name":"CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)","route":"/technologies/glioma-car-t/"},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/"}],"company":[{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/"},{"id":"modulari-t","kind":"company","name":"Modulari-T","route":"/companies/modulari-t/"},{"id":"tmunity-therapeutics","kind":"company","name":"Tmunity Therapeutics","route":"/companies/tmunity-therapeutics/"}],"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"idea":[{"id":"idea-moon-engineered-immune-surveillance","kind":"idea","name":"Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer","route":"/ideas/idea-moon-engineered-immune-surveillance/"},{"id":"idea-gd2-car-t-frontline-consolidation","kind":"idea","name":"GD2 CAR-T as consolidation in high-risk neuroblastoma","route":"/ideas/idea-gd2-car-t-frontline-consolidation/"},{"id":"idea-mesothelin-car-t-regional","kind":"idea","name":"Regionally delivered mesothelin CAR-T with PD-1 blockade","route":"/ideas/idea-mesothelin-car-t-regional/"}],"trial":[{"id":"gd2-cart01","kind":"trial","name":"GD2-CART01 (Bambino Gesù phase 1/2)","route":"/trials/gd2-cart01/"}],"roadmap":[{"id":"cell-therapy-roadmap","kind":"roadmap","name":"Cell therapy roadmap: CD19 CAR-T → solid tumours → in vivo CAR","route":"/roadmaps/cell-therapy-roadmap/"}],"person":[{"id":"christine-brown","kind":"person","name":"Christine E. Brown","route":"/people/christine-brown/"},{"id":"crystal-mackall","kind":"person","name":"Crystal L. Mackall","route":"/people/crystal-mackall/"},{"id":"marcela-maus","kind":"person","name":"Marcela V. Maus","route":"/people/marcela-maus/"},{"id":"renier-brentjens","kind":"person","name":"Renier J. Brentjens","route":"/people/renier-brentjens/"},{"id":"robbie-majzner","kind":"person","name":"Robbie G. Majzner","route":"/people/robbie-majzner/"}],"term":[{"id":"t-cell-exhaustion-term","kind":"term","name":"T-cell exhaustion and CAR-T persistence","route":"/terms/t-cell-exhaustion-term/"}],"pathway":[{"id":"nutrient-competition-tme","kind":"pathway","name":"Nutrient competition & metabolic immunosuppression","route":"/pathways/nutrient-competition-tme/"},{"id":"t-cell-exhaustion","kind":"pathway","name":"T-cell exhaustion","route":"/pathways/t-cell-exhaustion/"}]}}